

3rd TDM of Biologics SYMPOSIUM, 9 December 2022

Therapeutic drug monitoring of biologics:
towards personalised medicine

Program:

09.00 – 9.30 Introduction: Treatment of chronic inflammatory diseases in a personalised way
Dr Gertjan Wolbink, Reade, The Netherlands Reade

SESSION 1: Finding the Therapeutic window

Session chairs: Dr Annick de Vries & Dr Gertjan Wolbink

9.30 – 9.50 Use of TDM of biologics in rheumatology. Beyond the NOR-DRUM Study.

Dr Guro L Goll, Diakonhjemmet Hospital, Norway

9.50 – 10.10 Personalised dosing in multiple sclerosis, NEXT-MS and BLOOMS

Dr Zoe van Kempen, Amsterdam UMC, The Netherlands

10.10 – 10.30 Personalized dosing of biologics in dermatology; reduction and stopping

International Speaker (invited)

10.30 – 10.50 Optimal cut-off serum levels of biologics in IBD

Dr Krisztina Gecse, Amsterdam UMC, The Netherlands

10.50 – 11.10 Panel discussion

11.10 – 11.40 COFFEE BREAK

SESSION 2: Clinical use of biologics in different pathologies

Session chairs: Dr Theo Rispens, co-chair (invited)

11.40 – 11.55 Good use of expensive drug

Prof Sjoerd Repping, Zorgevaluatie en Gepast Gebruik and Amsterdam UMC, The Netherlands

11.55 – 12.10 Creating platform for TDM of biologics: European cooperation in Science and Technology, ENOTTA

Prof Denis Mulleman, Université de Tours, France

12.10 – 12.30 One biologic for multiple diseases, multiple biologics in one disease

Dr Floris Loeff, Sanquin, Amsterdam, the Netherlands

12.30 – 12.50 Dose individualization in oncology, a shot in the dark without pharmacokinetic/pharmacodynamic endpoints

Dr Rob ter Heine, Radboud University Medical Center,

12.50 – 13.05 Panel discussion

13.05 – 14.05 LUNCH

SESSION 3: Deeper understanding of the PK of biologics

Session chairs: Prof Ron Mathot, co-chair (invited)

- 14.05 – 14.30 Applying clinical pharmacology to enable the development of personalised/stratified medicines and the use of model-based drug development strategies
International Speaker (invited)
- 14.30 – 14.55 Mechanistic, Multi-Scale Mathematical Model of Immunogenicity for Therapeutic Proteins
Dr Timothy Hickling, Roche, Switzerland
- 14.55 – 15.20 Optimal structure of antibody therapeutics
National Speaker (invited)
- 15.20 – 15.40 Panel discussion
- 15.40- 16.10 TEA break

SESSION 4: Last hurdles to general implementation of TDM

Session chairs: Prof Geert D'Haens, Prof Phyllis Spuls

- 16.10 – 16:30 The pharmaceutical industry's view on TDM
Dr Laura I Salazar-Fontana, LAIZ Salazar Fontana Reg Science Consulting, Switzerland
- 16.30 – 16.50 Clinical application of dashboard systems
Dr Jurij Hanzel, University Medical Centre Ljubljana, Slovenia
- 16.50 – 17:10 Patient perspective on TDM
Maureen Leeuw, Reade, The Netherlands Reade
- 17.10 – 17.30 Panel discussion
- FAREWELL DRINKS and network reception